November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

New Monoclonal Antibody RSM01 Shows High Barrier to RSV Resistance in Laboratory Study

🥗 Nutrition 2 min read 👁 0

Researchers have evaluated a new extended half-life monoclonal antibody, RSM01, designed to protect against respiratory syncytial virus, finding it exhibits a strong barrier to viral resistance in laboratory settings.

🥗Nutrition

Key points

  • RSM01 is an investigational long-acting monoclonal antibody designed to combat RSV in low- and middle-income regions.
  • Laboratory tests showed that RSM01 induced only moderate resistance, unlike other tested antibodies that triggered high resistance.
  • The antibody successfully neutralized various contemporary global strains of the virus in in vitro assays.

A team of international researchers has published new findings on RSM01, an extended half-life monoclonal antibody engineered to prevent respiratory syncytial virus (RSV) infections, particularly in low- and middle-income regions. The study investigated the in vitro resistance barrier of the antibody alongside its effectiveness against a variety of global contemporary virus strains.

During laboratory evaluations conducted by scientists from institutions including the University Medical Center Utrecht and the Fred Hutchinson Cancer Center, viral strains were subjected to selective pressure from RSM01, nirsevimab, and palivizumab. While current licensed treatments such as palivizumab and nirsevimab prompted high resistance levels in tested RSV-A and RSV-B strains, exposure to RSM01 resulted in only moderate resistance without giving the mutant viruses a fitness advantage. Furthermore, neutralization assays demonstrated that RSM01 successfully targeted and neutralized circulating global clinical strains.

What to know: The findings suggest that RSM01 could serve as a viable alternative protection method if resistance issues arise with currently approved monoclonal antibodies. However, because this was an in vitro laboratory study using cell cultures, clinical trials and further observation are necessary to confirm how these results translate to human populations.

Readers should consult a healthcare professional for personalized medical guidance or decisions concerning infectious disease prevention and treatments.

Source Nature Health Sciences — nature.com/articles/s41467-026-79029-z ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.